In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.
Lunning Welcomes You to The Blood Club
Matthew Lunning, DO, is an associate professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center (UNMC). He serves as associate vice chair of research in the Department of Internal Medicine and as an assistant vice chancellor of clinical research at UNMC, and an at-large member of the Nebraska Medicine Medical Executive Committee. He is the host of the new podcast, The Blood Club.
As Dr Lunning explains, The Blood Club will take a deep dive into current issues in hematology/oncology in the clinic and in the laboratory, highlighting the most relevant trial data and its effect on the patient. He also promises a show that is willing to take a clear-eyed look at controversial topics in the field.
In this inaugural episode, Dr Lunning details some of the most important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant. Dr Lunning served as a co-director of the conference, along with Giants of Cancer Care award winners James O. Armitage, MD, and Julie M. Vose, MD, MBA.
Tycel Jovelle Phillips, MD, formerly a clinical associate professor with the University of Michigan Rogel Cancer Center who has since moved to City of Hope, gives a “great talk” on current treatment and potential future options for p53-mutated mantle cell lymphoma, Dr Lunning says. He praises Neha Mehta-Shah, MD, MSCI, associate professor in the Oncology Division at Washington University in St. Louis, for her “eloquent” presentation on the future of treatment for peripheral T cell lymphoma. Finally, Dr Lunning discusses a presentation from Stephen M. Ansell, MD, PhD, with Mayo Clinic, on the integration of novel options beyond CAR T-cell therapy for patients with non-Hodgkin lymphoma.